Design Therapeutics, Inc. Income Statement
DSGN|3 years of annual SEC 10-K data (FY2021-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 3 fiscal years. All figures from audited SEC 10-K filings.
Design Therapeutics, Inc. reported $0 in revenue and $50M in net loss for FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -6.59 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2021 |
|---|---|---|---|
| Revenue | $0 | $0 | $226.0K |
| SG&A Expense | $18.0M | $21.1M | $2.5M |
| R&D Expense | $44.4M | $57.1M | $6.1M |
| Operating Income | -$62.4M | -$78.2M | -$8.3M |
| Income Tax | $0 | - | - |
| Net Income | -$49.6M | -$66.9M | -$8.3M |
| EPS (Basic) | -$0.88 | -$1.19 | - |
| EPS (Diluted) | -$0.88 | -$1.19 | -$0.52 |
| Shares Outstanding | 56.8M | 56.5M | 16.0M |
| Operating Margin | - | - | -3685.8% |
| Profit Margin | - | - | -3663.7% |